These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20664003)

  • 1. Exploring the binding site crevice of a family B G protein-coupled receptor, the type 1 corticotropin releasing factor receptor.
    Gkountelias K; Papadokostaki M; Javitch JA; Liapakis G
    Mol Pharmacol; 2010 Oct; 78(4):785-93. PubMed ID: 20664003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding.
    Gkountelias K; Tselios T; Venihaki M; Deraos G; Lazaridis I; Rassouli O; Gravanis A; Liapakis G
    Mol Pharmacol; 2009 Apr; 75(4):793-800. PubMed ID: 19124613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
    Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
    Dautzenberg FM; Wille S
    Regul Pept; 2004 May; 118(3):165-73. PubMed ID: 15003833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that corticotropin-releasing factor receptor type 1 couples to Gs- and Gi-proteins through different conformations of its J-domain.
    Berger H; Heinrich N; Wietfeld D; Bienert M; Beyermann M
    Br J Pharmacol; 2006 Dec; 149(7):942-7. PubMed ID: 17057757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: contributions of the second membrane-spanning segment.
    Javitch JA; Ballesteros JA; Chen J; Chiappa V; Simpson MM
    Biochemistry; 1999 Jun; 38(25):7961-8. PubMed ID: 10387039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a Pachymedusa dacnicolor-Sauvagine analog as a new high-affinity radioligand for corticotropin-releasing factor receptor studies.
    Perrin MH; Tan LA; Vaughan JM; Lewis KA; Donaldson CJ; Miller C; Erchegyi J; Rivier JE; Sawchenko PE
    J Pharmacol Exp Ther; 2015 May; 353(2):307-17. PubMed ID: 25736419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors.
    Liaw CW; Grigoriadis DE; Lorang MT; De Souza EB; Maki RA
    Mol Endocrinol; 1997 Dec; 11(13):2048-53. PubMed ID: 9415408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation.
    Hoare SR; Fleck BA; Gross RS; Crowe PD; Williams JP; Grigoriadis DE
    Mol Pharmacol; 2008 May; 73(5):1371-80. PubMed ID: 18239030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
    Grigoriadis DE; Liu XJ; Vaughn J; Palmer SF; True CD; Vale WW; Ling N; De Souza EB
    Mol Pharmacol; 1996 Sep; 50(3):679-86. PubMed ID: 8794910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain.
    Beyermann M; Heinrich N; Fechner K; Furkert J; Zhang W; Kraetke O; Bienert M; Berger H
    Br J Pharmacol; 2007 Jul; 151(6):851-9. PubMed ID: 17533422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice.
    Javitch JA; Ballesteros JA; Weinstein H; Chen J
    Biochemistry; 1998 Jan; 37(4):998-1006. PubMed ID: 9454590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The three-dimensional structure of the N-terminal domain of corticotropin-releasing factor receptors: sushi domains and the B1 family of G protein-coupled receptors.
    Perrin MH; Grace CR; Riek R; Vale WW
    Ann N Y Acad Sci; 2006 Jul; 1070():105-19. PubMed ID: 16888152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment.
    Javitch JA; Fu D; Liapakis G; Chen J
    J Biol Chem; 1997 Jul; 272(30):18546-9. PubMed ID: 9228019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: evidence for possible CB2 deviation from a rhodopsin template.
    Zhang R; Hurst DP; Barnett-Norris J; Reggio PH; Song ZH
    Mol Pharmacol; 2005 Jul; 68(1):69-83. PubMed ID: 15840841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residues in the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice.
    Fu D; Ballesteros JA; Weinstein H; Chen J; Javitch JA
    Biochemistry; 1996 Sep; 35(35):11278-85. PubMed ID: 8784181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists.
    Hoare SR; Sullivan SK; Ling N; Crowe PD; Grigoriadis DE
    Mol Pharmacol; 2003 Mar; 63(3):751-65. PubMed ID: 12606786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
    Hoare SR; Sullivan SK; Fan J; Khongsaly K; Grigoriadis DE
    Peptides; 2005 Mar; 26(3):457-70. PubMed ID: 15652653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice.
    Javitch JA; Li X; Kaback J; Karlin A
    Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10355-9. PubMed ID: 7937955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice.
    Javitch JA; Fu D; Chen J
    Biochemistry; 1995 Dec; 34(50):16433-9. PubMed ID: 8845371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.